Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000665386 | SCV000789501 | likely pathogenic | GRACILE syndrome | 2017-02-03 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001062637 | SCV001227451 | pathogenic | not provided | 2022-01-18 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change affects BCS1L function (PMID: 11528392, 17314340). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt BCS1L protein function. ClinVar contains an entry for this variant (Variation ID: 6164). This missense change has been observed in individuals with complex III deficiency or GRACILE syndrome (PMID: 11528392, 20518024, 24655110, 29090881). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 99 of the BCS1L protein (p.Pro99Leu). |
Baylor Genetics | RCV003472985 | SCV004210825 | pathogenic | Pili torti-deafness syndrome | 2023-02-03 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001062637 | SCV005434033 | pathogenic | not provided | 2024-11-01 | criteria provided, single submitter | clinical testing | BCS1L: PM1, PM2, PM3, PP4:Moderate, PP3, PS3:Supporting |
OMIM | RCV000006539 | SCV000026722 | pathogenic | Mitochondrial complex III deficiency nuclear type 1 | 2001-09-01 | no assertion criteria provided | literature only |